Dorra Pharma Shines at CPHI Japan 2026, Forging a New Chapter of Asia-Pacific Pharmaceutical Cooperation with Innovative Strength

发布时间： 2026-04-24 阅读：46次

分享

From April 21 to 23, CPHI Japan 2026 grandly kicked off at Tokyo Big Sight. Showcasing its core small-molecule product portfolio, Dorra Pharma made a remarkable appearance at Booth #1B-05, demonstrating the robust innovative strength of Chinese pharmaceutical enterprises to global clients.

【Premium Product Portfolio Impresses Tokyo】
At the exhibition, through cutting-edge technology demonstrations, product promotions, and high-level customer negotiations, Dorra Pharma fully presented its fruitful achievements in global footprint expansion, green process development, and high-quality compliance systems. Covering widely recognized series for urinary tract infections, medications for neuropathic pain, and cutting‑edge intermediates for new metabolic drugs, Dorra Pharma attracted extensive attention and active engagement from both new and returning attendees, backed by deep technological expertise and highly competitive supply chain solutions.

【Focusing on Frontier Tracks to Empower Global Partners】
Notably, Dorra Pharma’s breakthrough development in the oligonucleotide drug sector, including phosphoramidite monomers, nucleic acid delivery carriers, and related raw materials, stood out as a major highlight at the exhibition. As a high-growth frontier field in global bio-pharmaceuticals, oligonucleotide drug R&D sets stringent requirements on raw material purity, structural diversity, and delivery systems. Leveraging its solid foundation in synthetic chemistry, Dorra Pharma launched a full‑spectrum portfolio of oligonucleotide raw materials, as well as key GalNAc and Linker intermediates, delivering one‑stop solutions from China for the R&D and production of oligonucleotide drugs to global pharmaceutical enterprises.

【Expanding Global Footprint, Advancing from China to the World】
In recent years, Dorra Pharma has continuously scaled up its internationalization efforts. By actively participating in global CPHI exhibitions and establishing localized communication systems, Dorra Pharma has built an efficient business network covering Asia‑Pacific, Europe, and North America. Through in‑depth exchanges with world‑leading pharmaceutical companies, Dorra Pharma is steadily evolving from a widely recognized industry player to a preferred collaboration partner. Driven by technological innovation, it delivers tangible value and taps into the global market with premium services and a sound compliance reputation.

Looking ahead, Dorra Pharma will continue to take innovation and quality as core pillars to deepen strategic mutual trust with global partners. We will promote high‑quality APIs, advanced pharmaceutical intermediates, and CDMO services worldwide, striving to grow into a globally leading, innovation‑driven ecosystem partner for the API industry.